Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of TPN171H on QT/QTc Intervals in Healthy Subjects
NCT05750355Phase 1Completed
- Sponsor
- Vigonvita Life Sciences
- Start
- Oct 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TPN171H in pulmonary arterial hypertension (PAH) (5 arms), sponsored by Vigonvita Life Sciences. Primary endpoint: QT Interval Corrected Using Fridericia's Formula. Started Oct 2022; status: completed.
02
Drugs
TPN171H
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT05750355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05750355.